In the present study, our goal was to investigate whether recombinant sgp130 could effectively suppress the IL-6 trans-signaling pathway and thereby suppress HepG2 cell growth as well as the development of HCC in DEN-treated mice. The gene discussed is IL6; the disease is hepatocellular carcinoma.